Cookies help us improve your ABPI online experience. If you accept their use, continue using our site. or, find out more about cookies.
Ukraine - UK Pharmaceutical Industry Response
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
ABPI 2021 Code of Practice
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
We represent our members, using their insight and experience to tell the story of how they change the lives of millions of people every day.
Medicines and vaccines are some of the most important ways we have to fight disease on a global scale and keep people fit and healthy.
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost effective before they can be used in the NHS.
Voluntary Scheme on branded medicines
The new 2019 Voluntary Scheme ‘VPAS’ is a commitment by industry, the NHS and Government to support innovation for the benefit of patients across the UK.
Once a new medicine is no longer covered by a patent it can be manufactured by any company around the world.
Improving access to medicines in the UK
The UK is a world leader in pharmaceutical research and development, and it is vital that NHS patients are able to access the latest treatments as fast as patients in other countries.
Future of medicine
With 7,000 medicines and vaccines in the global pipeline, the future of health looks exciting. The pharmaceutical industry is pioneering new treatments and new technologies that will change the face of modern medicine.
Innovating medicines funding in Scotland
Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure NHS Scotland uses treatments that are both cost and clinically effective.
What was the PPRS?
The UK has a number of different mechanisms for ensuring value for money and cost control in the NHS. In addition to NICE which evaluates cost-effectiveness, the Pharmaceutical Pricing Regulation Scheme (PPRS) helps controls the amount the NHS spends on new medicines.
NHS medicine spend
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost-effective before they can be used in the NHS.